TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Plasma Concentration (AUC) of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Walk 400 meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder Reconstruction Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Life Values
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client Satisfaction Questionnaire-8: Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of Session Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Skin cancer prevention activity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: D-E Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dual task function during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arteriovenous fistula flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of intervention-related safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of incomplete resection of the tumorectomy specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HbsAg negativation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence of enterococci resistant to vancomycin
Endpoint domain: Adverse events/effects
Primary endpoint: Emergence of EBLSE
Endpoint domain: Adverse events/effects
Primary endpoint: Emergence of Clostridium difficile
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to PMFT and BT (self efficacy)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuropsychological Test Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Better physical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less sick leaves
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Height-for-Age Z-score (HAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of non-heme iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of iron and micronutrient status indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily Cigarette Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Puff Volume/Puff Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon Monoxide (CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radial Pressure Pulse-wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in bone markers for bone resorption and formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Passage of Stone Fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Healing Index (H.I.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Visual Analogue Scale (VAS) of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects free from documented Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Result of allergen provocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite of CV Death, MI, Stroke and Stent Thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: BARC Bleeding Definition Type 2, 3 and 5
Endpoint domain: Adverse events/effects
Primary endpoint: Prediction of outcomes of interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Static Grip Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Grip Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in knee pain intensities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Caregiver Difficulties Scale (CDS)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Impact on family scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Organ volume change and damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Organ volume change and damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Organ volume change and damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: blood chemistries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number and frequency of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical deterioration or death
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) for Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measureable Concentration (AUClast) of Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White matter hyperintensity volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with at least one solicited adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically driven target lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional results in the sit to stand 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete ulcer closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decline in eGFR in mL/min per 1.73 m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in level of deoxyribonucleic acid (DNA) copy number in p53-related pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of mutation in p53-related pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of ribonucleic acid (RNA) expression in p53-related pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of protein expression in p53-related pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular and peri-papillary retinal vascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular and peri-papillary retinal infusion density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface of the macular avascular zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIPT clinical outcome performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: SARS-CoV-2 infection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Olfactory and gustatory loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK1349572 steady-state AUC(0-τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in non-perfused areas in different retinal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Presentation to emergency department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prolonged index hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Motor Impairment of Wrist and Forearm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sperm production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Speed of tooth movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Distance Walked in the 6-minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Without Sore Throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child problem behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Problematic parenting practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean Change From Baseline in Subjective Units of Distress Scale (SUDS) at End of Session 1
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum SUDS Rating During Crossover Exposure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of virological suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects meeting target growth AHV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of PX-866
Endpoint domain: Adverse events/effects
Primary endpoint: Safety profile of PX-866
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacodynamic measures of PX-866 on the PI-3K pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Measurement of plasma levels of BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of serum levels of BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Solicited AE Following Either Vaccination Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Time to occurrence of ILI and ARI
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of flux through the urea cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Clinical Global Impression - Severity (CGI-S) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of home and car no smoking rules
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sensitivity and specificity of dogs to detect COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of spontaneous expression of pain during injection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced swimming and running times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriuria five days after prostate biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving Hematocrit Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse Events leading to premature discontinuation of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: time of hematopoietic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory sensitivities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Score of International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0-24h (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Until Cmax (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance measurement of the i-STAT TBI Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with immune-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with new or worsening hematologic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects with new or worsening neurologic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: partial renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Asymmetric Dimethylarginine physiological marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Fibromyalgia Symptoms From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Events (AEs) of Grade II or Higher Per Patient
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of annual screening for CFRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rates of resident-related communication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antioxidant capacity in skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Appropriate action taken based on laboratory test or medication ordering
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of abnormal results and appropriate follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tests ordered but not performed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of any Serious Adverse Events (SAE) related to the study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any Grade 3 or higher AEs related to the study drug within 4 weeks after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Asthma Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exacerbations (Post-hoc Analysis of Annual Rates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total and Unbound Ribociclib and Everolimus AUC (0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median concentration Cmax of Ribociclib and Everolimus (0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD: highest dose of drug that did not cause a DLT in > 33% of participants
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Ischaemic Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Overall Response Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in estimated glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline of Strengths and Difficulties Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline of Kansas Parental Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline of PTSD Checklist for DSM-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Hospital Anxiety Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline General Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: body mass (weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy homeostasis outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical clock time in minutes (SCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Confirmation of measurement done with the investigational device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and effectiveness of sm-FBSG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of preterm deliveries
Endpoint domain: Mortality/survival
Primary endpoint: Patient control over the end effector
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of infection or irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Identify unique failure modes
Endpoint domain: Adverse events/effects
Primary endpoint: Identify trends in adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Oblique entry angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquired CV disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra-vaginal Ejaculation Latency Time (IELT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIEF-15 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: premature ejaculation symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of clinically significant corneal exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of rabies virus neutralizing antibody activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve for plasma phosphatidylcholine omega-3 fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical operation of peritoneal dialysis catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in BMD T-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Dyspnea Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple Sclerosis Questionnaire for Physical Therapists
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Grading FDA Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Adhesion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amelioration of Vaginal Dryness Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Efficacy of blocking the superior laryngeal nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of pain during forearm flexion recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of PREGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean Change in Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of AD16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-t of AD16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-∞ of AD16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand dynamometer value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes